To investigate the value of combining a targeted therapy with chemotherapy in NSCLC, we first tested the antitumor effect of a clinically approved EGFR TKI, afatinib, in combination with pemetrexed + cisplatin in a PDX model of EGFR L858R-mutated ADC (histological analysis in Figure 2a). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.